High-dose and low-dose systemic corticosteroids are equally efficient in acute severe asthma

Area of Science:

• Pulmonology
• Clinical Pharmacology

Background:

• The optimal dosage of systemic corticosteroids for acute severe asthma is not well-established.
• Current treatment guidelines recommend high-dose corticosteroids, but evidence comparing different doses is limited.

Purpose of the Study:

• To compare the efficacy of two doses of methylprednisolone in patients with acute severe asthma unresponsive to beta-2 agonists.
• To determine if high-dose methylprednisolone offers superior improvement in pulmonary function compared to low-dose.

Main Methods:

• A double-blind, randomized study involving 47 patients with acute severe asthma.
• Patients received either low-dose (1 mg/kg/day) or high-dose (6 mg/kg/day) methylprednisolone.
• Pulmonary function was assessed using serial bedside spirometry, with forced expiratory volume in one second (FEV1) as the primary outcome.

Main Results:

• Both low-dose and high-dose methylprednisolone groups showed similar improvements in pulmonary function.
• At 44 hours, mean FEV1 values were comparable between the groups (53% vs. 45% of predicted values).
• No statistically significant difference in FEV1 was observed between the low-dose and high-dose groups.

Conclusions:

• High-dose systemic corticosteroids do not provide additional benefit over low-dose methylprednisolone in treating severe acute asthma.
• Low-dose methylprednisolone appears to be an effective treatment option for acute severe asthma, simplifying treatment protocols.